Premium
S100A6 expression in fibrohistiocytic lesions
Author(s) -
Fullen D. R.,
Reed J. A.,
Finnerty B.,
McNutt N. S.
Publication year - 2001
Publication title -
journal of cutaneous pathology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.597
H-Index - 75
eISSN - 1600-0560
pISSN - 0303-6987
DOI - 10.1034/j.1600-0560.2001.028005229.x
Subject(s) - dermatofibrosarcoma protuberans , factor xiiia , pathology , atypical fibroxanthoma , medicine , immunohistochemistry , dermatopathology , dermatofibroma , myoepithelioma , dermatofibrosarcoma , dermis , myoepithelial cell
Background: S100A6, an S100 calcium‐binding protein, has been found in a variety of cutaneous and extracutaneous lesions including: melanocytic nevi, melanoma, some salivary gland and epithelial tumors, and malignant fibrous histiocytoma (MFH). Dermal dendrocytes (DD) in the papillary dermis of skin also express S100A6 protein. We evaluated a variety of cutaneous fibrohistiocytic lesions to determine if the immunophenotype of S100A6 positivity can be expanded to include some or all of these lesions. Methods: Formalin‐fixed, paraffin‐embedded tissues from fibrous papules (FP, 20), dermatofibromas (DF, 20), dermatofibrosarcoma protuberans (DFSP, 5), atypical fibroxanthomas (AFX, 5), oral fibromas (3), digital fibroma (1), and dermatomyofibroma (1) were evaluated with antibodies to S100A6, S100B, factor XIIIa, and MAC387 using a one‐hour capillary action‐based immunohistochemical procedure. Results: DD in 20/20 FP, 19/20 DF, and 4/4 fibromas stained positively with anti‐S100A6 in a pattern similar to anti‐factor XIIIa. No DFSP cases stained with anti‐S100A6. Anti‐S100A6 showed superior staining to anti‐factor XIIIa in 4/5 AFX cases. Conclusions: The immunophenotypes of some fibrohistiocytic lesions can be expanded to include S100A6 protein. With the exception of AFX, the use of anti‐S100A6 does not appear to offer added benefit over anti‐factor XIIIa in the differential diagnosis of fibrohistiocytic lesions.